<DOC>
	<DOCNO>NCT00700401</DOCNO>
	<brief_summary>This single arm study investigate predictive value week 4 virological response sustain virological response patient chronic hepatitis C , genotype 2 3 , treat PEGASYS + Copegus . Eligible patient treat PEGASYS 180 micrograms/week sc + Copegus 800mg/day po ; virological response week 4 continue treat 24 week , follow 24 week treatment-free follow-up . Non-responders week 4 enter separate protocol ( MV21371 ) receive PEGASYS + Copegus 24 48 week . The anticipated time study treatment 3-12 month , target sample size 100 individual .</brief_summary>
	<brief_title>POTENTE Study : A Study Early Virological Response Naive Patients With Chronic Hepatitis C , Genotype 2 3 , Treated With PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Plus Copegus ( Ribavirin ) .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; positive serum HCV RNA . coinfection HIV HBV ( patient positive HBsAg ) ; previous treatment interferon , peginterferon and/or ribavirin ; severe hepatic dysfunction decompensated cirrhosis liver .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>